Should I buy or sell Vir Biotechnology stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIR shares. View VIR analyst ratings or view top-rated stocks .

What is Vir Biotechnology's stock price target for 2024?

7 Wall Street research analysts have issued 1 year price targets for Vir Biotechnology's shares. Their VIR share price targets range from $10.00 to $110.00. On average, they predict the company's share price to reach $34.38 in the next twelve months. This suggests a possible upside of 301.1% from the stock's current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts .

How have VIR shares performed in 2024?

Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR stock has decreased by 14.8% and is now trading at $8.57. View the best growth stocks for 2024 here .

When is Vir Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our VIR earnings forecast .

How can I listen to Vir Biotechnology's earnings call?

Vir Biotechnology will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.28. The company had revenue of $16.80 million for the quarter, compared to analyst estimates of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative trailing twelve-month return on equity of 34.92%. The firm's revenue for the quarter was down 66.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.76) EPS.

What ETFs hold Vir Biotechnology's stock?

ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , Amplify Treatments, Testing and Advancements ETF (GERM) , ALPS Medical Breakthroughs ETF (SBIO) and First Trust Nasdaq Pharmaceuticals ETF (FTXH) . SPDR S&P 600 Small Cap ETF (SLY) .

What is George Scangos' approval rating as Vir Biotechnology's CEO?

7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com . George Scangos has an approval rating of 85% among the company's employees.

When did Vir Biotechnology IPO?

Vir Biotechnology (VIR) raised $149 million in an IPO on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO.

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ballentine Partners LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Ann M Hanly , Backer Marianne De, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos , Herbert Virgin , Howard Horn , Janet Napolitano , Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang , Robert J More, Robert J More , Saira Ramasastry , Steven J Rice , Sung Lee, Vicki L Sato and Vicki L Sato . View institutional ownership trends .

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VIR

Vir Biotechnology (VIR) Stock Price, News & Analysis

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Free VIR Stock Alerts

$8.57

-0.40 (-4.46%)

(As of 04/15/2024 ET)

Compare

Today's Range: $8.44
▼
$8.99
50-Day Range: $8.57
▼
$11.90
52-Week Range: $7.72
▼
$27.48

Volume: 769,575 shs
Average Volume: 1.05 million shs
Market Capitalization: $1.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.38

Get Vir Biotechnology alerts:

Vir Biotechnology MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 301.1% Upside
$34.38 Price Target
Short Interest: Healthy
5.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.71
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1.53 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.04) to ($3.87) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.92 out of 5 stars

Medical Sector

390th out of 929 stocks

Biological Products, Except Diagnostic Industry

56th out of 148 stocks

3.3

Analyst's Opinion

Consensus Rating
Vir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Vir Biotechnology has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.63% of the float of Vir Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Vir Biotechnology has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Vir Biotechnology has recently decreased by 8.66%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vir Biotechnology does not currently pay a dividend.
Dividend Growth
Vir Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIR.

2.1

News and Social Media Coverage

News Sentiment
Vir Biotechnology has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Vir Biotechnology this week, compared to 4 articles on an average week.
Search Interest
Only 6 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,525,844.00 in company stock.
Percentage Held by Insiders
18.10% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Vir Biotechnology are expected to grow in the coming year, from ($4.04) to ($3.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vir Biotechnology is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vir Biotechnology is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vir Biotechnology has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Vir Biotechnology Stock (NASDAQ:VIR)

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

VIR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VIR Stock News Headlines

April 5, 2024 | insidertrades.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells 72,995 Shares of Stock

April 3, 2024 | insidertrades.com

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $27,245.55 in Stock

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 29, 2024 | insidertrades.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Sells 6,008 Shares of Stock

April 11, 2024 | finance.yahoo.com

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

April 11, 2024 | businesswire.com

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

April 9, 2024 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts

April 6, 2024 | americanbankingnews.com

Backer Marianne De Sells 72,995 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 4, 2024 | finance.yahoo.com

Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares

March 21, 2024 | finance.yahoo.com

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio

March 19, 2024 | investorplace.com

From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires

March 16, 2024 | ca.finance.yahoo.com

VIR Jul 2024 17.500 call

March 15, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)

March 15, 2024 | finance.yahoo.com

Vir Biotechnology, Inc. (VIR)

March 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning

March 8, 2024 | markets.businessinsider.com

Maintaining Buy Rating on ONCY Amidst Promising Clinical Advancements and Partnership Potential

March 5, 2024 | finance.yahoo.com

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

February 29, 2024 | finance.yahoo.com

VIR Oct 2024 20.000 call

February 28, 2024 | seekingalpha.com

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

February 26, 2024 | realmoney.thestreet.com

These 2 Biotech Stocks Are Rising Against the Recent Small-Caps Downtrend

February 26, 2024 | investorplace.com

3 Highly Rated Biotech Stocks to Buy for 300% Gains

February 26, 2024 | markets.businessinsider.com

Optimistic Outlook for Vir Biotechnology’s Clinical Programs and Financial Position Reinforces Buy Rating

February 25, 2024 | msn.com

Vir Biotechnology (VIR) Price Target Increased by 9.93% to 33.08

February 23, 2024 | markets.businessinsider.com

Optimistic Buy Rating on Vir Biotechnology Amidst Advancing HDV and HBV Programs and Upcoming Clinical Catalysts

February 23, 2024 | markets.businessinsider.com

Strong Buy Rating for Vir Biotechnology on Promising Hepatitis Pipeline and Market Leadership Potential

February 23, 2024 | finance.yahoo.com

Q4 2023 Vir Biotechnology Inc Earnings Call

See More Headlines

Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/15/2024
Next Earnings (Confirmed): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:VIR
CUSIP: N/A
CIK: 1706431
Web: www.vir.bio
Phone: 415-906-4324
Fax: N/A
Employees: 587
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $34.38
High Stock Price Target: $110.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +301.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-615,060,000.00
Net Margins: -713.69%
Pretax Margin: -728.93%
Return on Equity: -34.92%
Return on Assets: -27.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.05
Quick Ratio: 9.05

Sales & Book Value

Annual Sales: $86.18 million
Price / Sales: 13.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.82 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 134,500,000
Free Float: 110,156,000
Market Cap: $1.15 billion
Optionable: Optionable
Beta: 0.41

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Ann M. Hanly Ph.D. (Age 53)
Executive VP & Chief Technology Officer
Comp: $842.23k
Dr. Phillip Pang M.D. (Age 48)
Ph.D., Executive VP & Chief Medical Officer
Comp: $837.38k
Dr. Marianne De Backer M.B.A. (Age 54)
M.Sc., Ph.D., CEO & Director
Dr. Klaus Frueh Ph.D. (Age 64)
Co-Founder & Scientific Advisor
Comp: $177.66k
Dr. Lawrence Corey M.D. (Age 76)
Co-Founder & Scientific Advisor
Dr. Louis J. Picker M.D.
Co-Founder & Scientific Advisor
Mr. Sung H. Lee (Age 54)
Executive VP & CFO
Dr. Jennifer Eileen Towne Ph.D.
Executive VP & Chief Scientific Officer
Ms. Heather Rowe Armstrong
Vice President of Investor Relations
Ms. Vanina De Verneuil J.D.
Executive VP, General Counsel & Corporate Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VIR Stock Analysis - Frequently Asked Questions

Should I buy or sell Vir Biotechnology stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIR shares.
View VIR analyst ratings or view top-rated stocks.
What is Vir Biotechnology's stock price target for 2024?: 7 Wall Street research analysts have issued 1 year price targets for Vir Biotechnology's shares. Their VIR share price targets range from $10.00 to $110.00. On average, they predict the company's share price to reach $34.38 in the next twelve months. This suggests a possible upside of 301.1% from the stock's current price.
View analysts price targets for VIR or view top-rated stocks among Wall Street analysts.
How have VIR shares performed in 2024?: Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR stock has decreased by 14.8% and is now trading at $8.57.
View the best growth stocks for 2024 here.
When is Vir Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VIR earnings forecast.
How can I listen to Vir Biotechnology's earnings call?: Vir Biotechnology will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Vir Biotechnology's earnings last quarter?: Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.28. The company had revenue of $16.80 million for the quarter, compared to analyst estimates of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative trailing twelve-month return on equity of 34.92%. The firm's revenue for the quarter was down 66.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.76) EPS.

What ETFs hold Vir Biotechnology's stock?: ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).SPDR S&P 600 Small Cap ETF (SLY).
What is George Scangos' approval rating as Vir Biotechnology's CEO?: 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.
When did Vir Biotechnology IPO?: Vir Biotechnology (VIR) raised $149 million in an IPO on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO.
Who are Vir Biotechnology's major shareholders?: Vir Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ballentine Partners LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Ann M Hanly, Backer Marianne De, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Sung Lee, Vicki L Sato and Vicki L Sato.
View institutional ownership trends.
How do I buy shares of Vir Biotechnology?: Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIR) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial